Which has the lower trailing P/E, IDXX or RMD?

RMD has the lower trailing P/E: IDXX trades at 41.88 and RMD at 20.81. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, IDXX or RMD?

Over the past five years, RMD grew revenue faster — IDXX at a 9.24% CAGR versus RMD at 12.37%.

Does IDXX or RMD pay a bigger dividend?

RMD pays a dividend (1.12% yield), while IDXX has no payments in the available dividend history.

Is IDXX or RMD more profitable?

RMD runs the higher net margin — IDXX at 24.63% versus RMD at 27.44%.

How have IDXX and RMD total returns compared?

Over the past 10 years, IDXX delivered 18.06% and RMD delivered 13.36% annualized total return. Past performance doesn't predict future results.

IDEXX Laboratories, Inc. (IDXX) vs ResMed Inc. (RMD)

A side-by-side comparison of IDEXX Laboratories, Inc. and ResMed Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 4, 2026. Differences are shown without an overall score or investment verdict.

IDXX

IDEXX Laboratories, Inc.

$46.39B

$588.09HealthcareDelayed quote: Aug 4, 2026, 4:00 PM EDT

RMD

ResMed Inc.

$32.37B

$223.14HealthcareDelayed quote: Aug 4, 2026, 4:00 PM EDT

Total return — IDXX vs RMD

growth of $100 · dividends reinvested · last 30y

IDXX +12164.4%RMD +25940.2%RMD compounded faster

IDXX RMD

IDXX vs RMD: by the numbers

•IDXX is the larger company ($46.39B vs $32.37B market cap).
•RMD trades at the lower trailing earnings multiple (20.81 vs 41.88 P/E), one valuation lens rather than an overall verdict.
•RMD converts more revenue to profit (27.44% vs 24.63% net margin).
•RMD grew revenue faster over the past five years (12.37% vs 9.24% CAGR).
•RMD pays a dividend (1.12% yield), while IDXX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	IDXX	RMD
P/E ratio	41.88	20.81
Forward P/E	38.77	19.34
P/S ratio	10.30	5.71
P/B ratio	29.44	4.87
PEG ratio	2.31	0.72
EV / EBITDA	30.04	14.32
FCF yield	2.36%	5.52%

Profitability

Metric	IDXX	RMD
Gross margin	62.05%	61.69%
Operating margin	31.63%	34.28%
Net margin	24.63%	27.44%
ROE	70.38%	23.41%
ROIC	40.27%	19.56%

Dividends

Metric	IDXX	RMD
Dividend yield	N/A	1.12%
Payout ratio	N/A	25.13%

Growth (annualized)

Metric	IDXX	RMD
Revenue CAGR (5Y)	9.24%	12.37%
EPS CAGR (5Y)	14.07%	17.25%
FCF CAGR (5Y)	10.13%	18.98%
Total return CAGR (5Y)	-3.98%	-3.81%

Frequently asked

Which has the lower trailing P/E, IDXX or RMD?: RMD has the lower trailing P/E: IDXX trades at 41.88 and RMD at 20.81. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, IDXX or RMD?: Over the past five years, RMD grew revenue faster — IDXX at a 9.24% CAGR versus RMD at 12.37%.
Does IDXX or RMD pay a bigger dividend?: RMD pays a dividend (1.12% yield), while IDXX has no payments in the available dividend history.
Is IDXX or RMD more profitable?: RMD runs the higher net margin — IDXX at 24.63% versus RMD at 27.44%.
How have IDXX and RMD total returns compared?: Over the past 10 years, IDXX delivered 18.06% and RMD delivered 13.36% annualized total return. Past performance doesn't predict future results.

Go deeper

Full IDXX analysis Full RMD analysis Interactive comparison tool

Dig into the metrics

IDEXX Laboratories P/E ratio ResMed P/E ratio IDEXX Laboratories dividend yield ResMed dividend yield IDEXX Laboratories ROE ResMed ROE IDEXX Laboratories operating margin ResMed operating margin IDEXX Laboratories revenue growth ResMed revenue growth IDEXX Laboratories free cash flow ResMed free cash flow

IDEXX Laboratories & ResMed appear in these rankings

Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 4, 2026.